Division of Integrative Systems Medicine and Digestive Disease, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Gut. 2019 Oct;68(10):1791-1800. doi: 10.1136/gutjnl-2018-317842. Epub 2019 Feb 11.
OBJECTIVE: Faecal microbiota transplant (FMT) effectively treats recurrent infection (rCDI), but its mechanisms of action remain poorly defined. Certain bile acids affect germination or vegetative growth. We hypothesised that loss of gut microbiota-derived bile salt hydrolases (BSHs) predisposes to CDI by perturbing gut bile metabolism, and that BSH restitution is a key mediator of FMT's efficacy in treating the condition. DESIGN: Using stool collected from patients and donors pre-FMT/post-FMT for rCDI, we performed 16S rRNA gene sequencing, ultra performance liquid chromatography mass spectrometry (UPLC-MS) bile acid profiling, BSH activity measurement, and qPCR of /CD genes involved in bile metabolism. Human data were validated in batch cultures and a C57BL/6 mouse model of rCDI. RESULTS: From metataxonomics, pre-FMT stool demonstrated a reduced proportion of BSH-producing bacterial species compared with donors/post-FMT. Pre-FMT stool was enriched in taurocholic acid (TCA, a potent germinant); TCA levels negatively correlated with key bacterial genera containing BSH-producing organisms. Post-FMT samples demonstrated recovered BSH activity and /CD gene copy number compared with pretreatment (p<0.05). In batch cultures, supernatant from engineered -expressing and naturally BSH-producing organisms ( and ) reduced TCA-mediated germination relative to culture supernatant of wild-type (BSH-negative) total viable counts were ~70% reduced in an rCDI mouse model after administration of expressing highly active BSH relative to mice administered BSH-negative (p<0.05). CONCLUSION: Restoration of gut BSH functionality contributes to the efficacy of FMT in treating rCDI.
目的:粪便微生物群移植(FMT)有效地治疗复发性感染(rCDI),但其作用机制仍未明确定义。某些胆汁酸会影响发芽或营养生长。我们假设肠道微生物群衍生的胆盐水解酶(BSH)的丧失会通过扰乱肠道胆汁代谢而导致 CDI,并且 BSH 的恢复是 FMT 治疗该疾病疗效的关键介质。
设计:使用来自患者和供体 rCDI 治疗前/后的粪便进行 16S rRNA 基因测序、超高效液相色谱-质谱(UPLC-MS)胆汁酸分析、BSH 活性测定以及涉及胆汁代谢的 /CD 基因的 qPCR。人类数据在批培养和 rCDI 的 C57BL/6 小鼠模型中得到了验证。
结果:从宏基因组学分析来看,rCDI 治疗前的粪便中与供体/治疗后的粪便相比,产生 BSH 的细菌种类比例降低。rCDI 治疗前的粪便中富含牛磺胆酸(TCA,一种有效的发芽剂);TCA 水平与含有 BSH 产生菌的关键细菌属呈负相关。与治疗前相比,治疗后的样本显示 BSH 活性和 /CD 基因拷贝数得到恢复(p<0.05)。在批培养中,表达的 和天然产生 BSH 的 ( 和 )的上清液可降低 TCA 介导的 发芽,与野生型(BSH 阴性)的培养上清液相比,rCDI 小鼠模型中表达高活性 BSH 的 给药后 TCA 介导的 发芽率降低了约 70%,而给予 BSH 阴性 的小鼠则降低了(p<0.05)。
结论:肠道 BSH 功能的恢复有助于 FMT 治疗 rCDI 的疗效。
Gastroenterology. 2018-7-17
Cochrane Database Syst Rev. 2023-4-25
Cell Host Microbe. 2025-3-12
Front Microbiol. 2025-2-12
J Bacteriol. 2025-3-20
Gastroenterology. 2018-7-17